Log in

NASDAQ:CBAYCymaBay Therapeutics Stock Price, Forecast & News

$6.90
+0.64 (+10.22 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.08
Now: $6.90
$7.09
50-Day Range
$3.32
MA: $3.96
$6.26
52-Week Range
$1.21
Now: $6.90
$7.09
Volume9.66 million shs
Average Volume7.31 million shs
Market Capitalization$475.27 million
P/E RatioN/A
Dividend YieldN/A
Beta1.38
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Read More
CymaBay Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBAY
CUSIPN/A
Phone510-293-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10 million
Book Value$2.71 per share

Profitability

Net Income$-102,810,000.00

Miscellaneous

Employees43
Market Cap$475.27 million
Next Earnings DateN/A
OptionableOptionable
$6.90
+0.64 (+10.22 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

How has CymaBay Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

CymaBay Therapeutics' stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CBAY stock has increased by 348.1% and is now trading at $6.90.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of CymaBay Therapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CymaBay Therapeutics
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics Inc (NASDAQ:CBAY) posted its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07.
View CymaBay Therapeutics' earnings history
.

What price target have analysts set for CBAY?

12 brokerages have issued 1-year price targets for CymaBay Therapeutics' shares. Their forecasts range from $6.00 to $20.00. On average, they expect CymaBay Therapeutics' stock price to reach $11.73 in the next year. This suggests a possible upside of 70.0% from the stock's current price.
View analysts' price targets for CymaBay Therapeutics
.

Has CymaBay Therapeutics been receiving favorable news coverage?

Headlines about CBAY stock have been trending positive this week, according to InfoTrie. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CymaBay Therapeutics earned a daily sentiment score of 2.8 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.
View the latest news about CymaBay Therapeutics
.

Who are some of CymaBay Therapeutics' key competitors?

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), TG Therapeutics (TGTX), Opko Health (OPK), AT&T (T), Pfizer (PFE), Square (SQ) and Corbus Pharmaceuticals (CRBP).

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the following people:
  • Mr. Sujal A. Shah, Pres, CEO & Director (Age 46)
  • Mr. Daniel Menold, VP of Fin. (Age 49)
  • Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 64)
  • Mr. Paul T. Quinlan, Gen. Counsel & Corp. Sec. (Age 56)
  • Dr. Pol F. Boudes, Chief Medical Officer (Age 62)

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include UBS Group AG (0.55%), WINTON GROUP Ltd (0.09%), SG Americas Securities LLC (0.06%), ProShare Advisors LLC (0.03%), State Board of Administration of Florida Retirement System (0.02%) and Russell Investments Group Ltd. (0.01%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Daniel Menold, Kurt Von Emster and Sujal Shah.
View institutional ownership trends for CymaBay Therapeutics
.

Which major investors are buying CymaBay Therapeutics stock?

CBAY stock was acquired by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, SG Americas Securities LLC, Russell Investments Group Ltd., UBS Group AG, ProShare Advisors LLC, and State Board of Administration of Florida Retirement System.
View insider buying and selling activity for CymaBay Therapeutics
.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $6.90.

How big of a company is CymaBay Therapeutics?

CymaBay Therapeutics has a market capitalization of $475.27 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-102,810,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. CymaBay Therapeutics employs 43 workers across the globe.

What is CymaBay Therapeutics' official website?

The official website for CymaBay Therapeutics is www.cymabay.com.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.